Orchid Pharma reports positive EBIDTA in Q2
The company is focussed on increasing the capacity utilizations while controlling costs
The company is focussed on increasing the capacity utilizations while controlling costs
The company sees the business reaching $100mn
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The company is making its entry into the Hyderabad market through its unique asset-light business model
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated